SAR439859

Unassigned

New Medicines

Metastatic breast cancer - second- or third-line

Information

New molecular entity
Sanofi
Sanofi

Development and Regulatory status

Phase II Clinical Trials
Phase II Clinical Trials
Phase II Clinical Trials

Category

Selective estrogen receptor degrader (SERD)
In 2012, the estimated age-adjusted annual incidence of breast cancer in 40 European countries was 94.2 per 100,000 and the mortality 23.1 per 100,000 [1].
Metastatic breast cancer - second- or third-line
Oral